Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Primary Malignant Peripheral Nerve Sheath Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory 1

Interventions

Temozolomide 5Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2vocimagene amiretrorepvec 1trametinib 1dabrafenib 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Standard of Care 1Spinal Puncture 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiation 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1Outcome Assessment, Health Care 1Observational Studies as Topic 1Ketoconazole 1Irinotecan 1Heart Rate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Eflornithine 1Diphtheria-Tetanus Vaccine 1DNA 1Craniotomy 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × Vorinostat × 90 days × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡